← FDA DRUG APPROVALS

FDA ANDA · ANDA088584

DHC PLUS

Sponsor: PHARM RES ASSOC

APPLICATION
ANDA088584
TYPE
ANDA
ORIGINAL APPROVAL
1986-03-04
LATEST ACTION
1998-05-04
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

DHC PLUSDiscontinued
ACETAMINOPHEN 356.4MG, CAFFEINE 30MG, DIHYDROCODEINE BITARTRATE 16MG · CAPSULE · ORAL

Approval history

1998-05-04Labeling · Supplement 16AP
1994-06-09Labeling · Supplement 10AP
1994-02-24Labeling · Supplement 8AP
1993-05-12Labeling · Supplement 7AP
1993-04-16Labeling · Supplement 6AP
1989-06-07Labeling · Supplement 5AP
1986-03-04OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →